Results 101 to 110 of about 29,746 (162)

Anlotinib plus penpulimab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis from the perspective of the Chinese healthcare system. [PDF]

Front Oncol
Bai G, Yang H, Ge W, Yang R, Yu T, Qi R.
europepmc   +1 more source

Cost-effectiveness analysis of nab-paclitaxel with or without relacorilant for platinum-resistant ovarian cancer. [PDF]

J Ovarian Res
Lai S, Lai S, Xu X, Huang W, Chen Q, He S, Xue H.   +6 more
europepmc   +1 more source

Cost-effectiveness analysis of neoadjuvant docetaxel plus androgen deprivation therapy before radical prostatectomy in high-risk localized prostate cancer. [PDF]

Front Public Health
Liu Q, Wang Y, Yuan W, Chen J, Tian F, Zhan M, Guo M.   +6 more
europepmc   +1 more source

Cost-effectiveness of optical coherence tomography-guided percutaneous coronary intervention for patients with complex coronary artery lesions in China: a markov model-based study. [PDF]

Cost Eff Resour Alloc
Jiang X, Zhou Y, Chen Y, Yan T, Du S, Sang H.   +5 more
europepmc   +1 more source

Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy. [PDF]

Clinicoecon Outcomes Res
Ghetti G, Castello L, Odonde LA, De Fazio S, Stella A, Bruno A, Marchionne E, Bonifacio M.   +7 more
europepmc   +1 more source

Theoretical Cost-Effectiveness of PCSK9 Inhibitors in Stroke Due to Intracranial Atherosclerosis.

JAMA Netw Open
Kellogg C, Badillo Goicoechea E, Kim DD, Yaghi S, Chaturvedi S, Mehendale R, Orjuela K, Kass-Hout T, Morsi RZ, Morales J, Singh E, Jhaveri A, Prabhakaran S, Smith MM, Brorson JR, Golani S, Mazuera S, Kang R, Eltatawy A, Pillajo J, Siegler JE.   +20 more
europepmc   +1 more source

Health economic evaluation of an interdisciplinary care pathway for older patients with vertigo, dizziness and balance disorders in primary care (MobilE-PHY2) - a cluster-randomised trial. [PDF]

Cost Eff Resour Alloc
Zimmer V, Horstmannshoff C, Bauer P, Borchers P, Scheibe S, Voigt K, Müller M, Köberlein-Neu J.   +7 more
europepmc   +1 more source

Health economic evaluation of Mirvetuximab soravtansine for the treatment of FRα-positive, platinum resistant ovarian cancer in Germany. [PDF]

J Cancer Res Clin Oncol
Janke FF, Baldessarini RJ, Bauerschlag D, Zibolka S, Hartmann M.   +4 more
europepmc   +1 more source

Economic evaluation of robotic-assisted versus manual total hip arthroplasty: a systematic review of cost and clinical outcomes. [PDF]

EFORT Open Rev
Wignadasan W, Dragonas C, Fontalis A, Berna MJ, Putzeys P, Patel R, Haddad FS.   +6 more
europepmc   +1 more source

Valuing Mortality Risk Reductions and Health Improvements: A Life Expectancy Framework to Harmonize Policy Traditions. [PDF]

Risk Anal
Nielsen JS, Chilton S, McDonald R.
europepmc   +1 more source